Tag

Chinook Therapeutics

All articles tagged with #chinook therapeutics

business3 years ago•2 min saved

Trending Stocks: Carnival, Nasdaq, Oracle, KeyCorp, Illumina CEO Steps Down and More

Carnival's stock rallied 13% after being upgraded by JPMorgan and Bank of America, while Nasdaq's shares fell 11% after announcing its acquisition of Adenza. Chinook Therapeutics' shares soared 58% after Novartis agreed to acquire the biotech firm for up to $3.5 billion. Oracle's shares gained 5.5% ahead of its quarterly earnings announcement, and Nio's stock added 9% after cutting prices for its vehicles. KeyCorp's stock slipped nearly 6% after the company said net interest income is going to come in softer than expected.

via CNBC|

#business #carnival #chinook-therapeutics

business3 years ago•0 min saved

Novartis Acquires Chinook Therapeutics for $3.5 Billion to Boost Kidney Disease Treatments.

Novartis has agreed to acquire Chinook Therapeutics, a biopharma company, for up to $3.5 billion. Chinook's stock surged following the announcement.

via Barron's|

#acquisition #biopharma #business

healthcare3 years ago•0 min saved

Novartis acquires Chinook Therapeutics for $3.5B to advance kidney disease treatment.

Novartis is set to acquire Chinook Therapeutics, a biotech company focused on kidney disease, for $3.2 billion in cash. The acquisition includes two late-stage drugs for a rare chronic kidney disease. Novartis already has a top drug for IgA nephropathy, but Chinook's atrasentan and zigakibart could provide additional options for patients.

via Endpoints News|

#acquisition #biotech #chinook-therapeutics

business3 years ago•2 min saved

Novartis acquires Chinook Therapeutics for $3.2-3.5 billion to boost late-stage pipeline.

Novartis has agreed to acquire Chinook Therapeutics for up to $3.5 billion to boost its late-stage drug development line-up with a new treatment for a rare severe kidney disease. The merger is expected to close in the second half of 2023. Chinook shareholders would receive $3.2 billion, or $40 per share, in cash plus a contingent value right worth up to $300 million. Novartis CEO Vas Narasimhan is eager to raise the prospect of future blockbuster drugs after leading a push to reshape the Swiss drugmaker to focus on fewer therapeutic areas and the most promising geographic markets.

via Reuters|

#business #chinook-therapeutics #drug-development